Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending dose (‘MAD’) trial, eight healthy human volunteers were randomly assigned 1:1 to 1 dose of PRV-003 or placebo for five consecutive days,” the article reads. “Evaluated by the Safety Review Committee, no serious adverse events were recorded, and all patients demonstrated normal vital signs, electrocardiogram readings and breathing function. In total, the phase 1 trial was designed with six cohorts comprised of eight individuals each, with data expected to be reported after each cohort is completed.”
“After reviewing the data from MAD Cohort I, I have strong confidence that PRV-002 will continue to show safety during the final, high-dose MAD portion of the phase 1 clinical trial. We have unanimously approved the start of MAD Cohort II,” Dallas Hack, MD, member of the Safety Review Committee, said in a statement.* “The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects.”
To view the full article, visit https://ibn.fm/uwump
About Odyssey Health Inc. (formerly Odyssey Group International Inc.)
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information about the company, visit www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
*Odyssey Health achieves positive safety outcomes for concussion drug in multiple ascending dosing trial. Odyssey Health. August 18, 2022. Accessed August 23, 2022. https://www.globenewswire.com/news-release/2022/08/18/2500777/0/en/Odyssey-Health-Achieves-Positive-Safety-Outcomes-for-Concussion-Drug-in-Multiple-Ascending-Dosing-Trial.html
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
